---
title: "Eli Lilly will launch late-stage trials for its amylin-based weight loss drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264676832.md"
description: "Eli Lilly stated that after its experimental insulin weight-loss drug showed positive results in mid-term studies, it will begin late-stage trials next month. The company indicated that the highest weekly dose of Irlaglutide can help obese or overweight patients lose an average of 20.1% of their weight over 48 weeks"
datetime: "2025-11-06T13:49:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264676832.md)
  - [en](https://longbridge.com/en/news/264676832.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264676832.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264676832.md) | [繁體中文](https://longbridge.com/zh-HK/news/264676832.md)


# Eli Lilly will launch late-stage trials for its amylin-based weight loss drug

Eli Lilly (LLY.US) stated that after its experimental glucagon-like peptide-1 weight loss drug showed positive results in mid-stage studies, it will begin late-stage trials next month.

The company indicated that weekly injections of the maximum dose of eloralin can help obese or overweight patients lose an average of 20.1% of their weight over 48 weeks

### Related Stocks

- [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/en/news/281171668.md)
- [InSilico Medicine's Loss Widens in 2025; Enters Licensing Agreement With Eli Lilly](https://longbridge.com/en/news/280951810.md)
- [NEUBERGER ENERGY INFRASTRUCTURE AND INCOME FUND ANNOUNCES INCREASE IN DISTRIBUTION RATE AND DECLARATION OF NEXT MONTHLY DISTRIBUTION | NML Stock News](https://longbridge.com/en/news/280684404.md)
- [India's Vedanta to split into five companies next month, FT reports](https://longbridge.com/en/news/280936382.md)
- [Eli Lilly Stock (LLY) Gets a Boost From Latest Trial Results. It Has Nothing to Do with Obesity Drugs](https://longbridge.com/en/news/280811478.md)